Healthcare ❯ Pharmaceuticals

Vaccine Development

Clinical Trials COVID-19 Vaccines mRNA Technology mRNA Vaccines Public Health Nasal Spray Vaccines Covid-19 Regulatory Approval International Cooperation Market Competition COVID-19 Emergency Use Authorization Adverse Effects Moderna Regulatory Oversight Protein-based Vaccines Bavarian Nordic Market Impact Regulatory Affairs Regulatory Agencies Covid-19 Vaccine Approval Legal Issues Vaccine Manufacturing Vaccine Efficacy AstraZeneca Vaccine Safety Future Vaccines

Pfizer and BioNTech Halt U.S. COVID Vaccine Trial for 50–64-Year-Olds Over Slow Enrollment

Tougher FDA rules are squeezing efforts to test shots in healthy adults 50 to 64.

FDA Weighs Ending Pfizer COVID-19 Authorization for Children Under 5

Moderna Cuts 10% of Global Workforce in Major Cost Overhaul

FDA Approves Moderna’s mNEXSPIKE for Seniors and High-Risk Adults as CDC Drops Recommendations for Healthy Children and Pregnant Women

FDA Grants Limited Approval to Novavax’s COVID-19 Vaccine